Zacks Investment Research downgraded Novartis AG (ADR) (NYSE:NVS) to Sell in a report released today.
- Updated: September 25, 2016
Zacks Investment Research has downgraded Novartis AG (ADR) (NYSE:NVS) to Sell in a report released on Wednesday September 21, 2016.
Previously on 9/20/2016, Chardan Capital released a statement about Novartis AG (ADR) (NYSE:NVS) increased the target price from $0.00 to $95.00. At the time, this indicated a possible upside of 0.19%.
Just yesterday Novartis AG (ADR) (NYSE:NVS) traded -0.67% lower at $81.06. Novartis AG (ADR)’s 50-day moving average is $80.71 and its 200-day moving average is $78.44. The last stock price is up 3.87% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,031,218 shares of NVS traded hands, down from an average trading volume of 1,359,970
Recent Performance Chart
Novartis AG (ADR) has 52 week low of $69.90 and a 52 week high of $95.11 with a price-earnings ratio of 29.09 and has a total market value of $0.
A total of 4 firms have issued a report on NVS. Two equity analysts rating the company a strong buy, one brokerage rating the stock a buy, 1 brokerage rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 equity analysts rating the company a sell with a one year target of $94.50.
Brief Synopsis On Novartis AG (ADR) (NYSE:NVS)
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.